|
KR20190085952A
|
|
Helicobacter pylori - An improved method for the detection of atrophic gastritis with gastritis and related risks
|
|
AU2016219701A1
|
|
Preparation and a component intended to be added to a tobacco product
|
|
WO2016128624A1
|
|
Fecal immunochemical test for screening of colorectal neoplasia
|
|
WO2015189479A1
|
|
Composition containing cysteine or a derivative thereof for the treatment or prevention of acute hypersensitivities
|
|
FI20155150A
|
|
Composition for preventing hangover symptoms
|
|
WO2015132472A1
|
|
Composition for binding aldehydes and free radicals in the gastrointestinal tract
|
|
AU2014259550A1
|
|
Preparation and a component intended to be added to a tobacco product
|
|
CN105242045A
|
|
Use of gastrin-17 as biomarker for atrophic gastritis with increased risk of several related sequels
|
|
FI20145806A
|
|
Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions
|
|
FI20135503A
|
|
Cysteine or its derivatives for the treatment of atrophic gastritis
|
|
MX2015006175A
|
|
Encapsulated composition for binding aldehydes in the stomach.
|
|
MX2015012613A
|
|
Composition for oral administration for binding aldehydes in the gastrointestinal tract.
|
|
FI20135097A
|
|
Composition for binding aldehydes in the mouth
|
|
FI20125570A
|
|
A composition for preventing headaches
|
|
CA2831650A1
|
|
Medical products for use in conditions related to microbial infections in the upper aerodigestive tract
|
|
FI20116022A0
|
|
A method for determining Helicobacter pylori infections and related diseases or conditions
|
|
FI20115680A0
|
|
Liquid pharmaceutical compositions or combination products
|
|
US2011171296A1
|
|
Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
|
|
AU2011100052A4
|
|
Method and preparartion for binding acetaldehyde in the stomach
|
|
FI20106276A0
|
|
A method for detecting the presence of faecal occult blood in stool
|
